FTC litigator: agency eyes REMS abuse as pay-for-delay wanes
As fewer drugmakers cut reverse-payment deals, the Federal Trade Commission is keeping a close eye on pharmaceutical companies that abuse safety protocols to prevent competition, one of the agency’s top litigators has said.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10